Re-evaluating the role of BCR/ABL in chronic myelogenous leukemia

Chronic myelogenous leukemia (CML) requires the BCR/ABL tyrosine kinase for disease onset and maintenance. As a result, CML can be successfully treated with tyrosine kinase inhibitors (TKIs) such as imatinib. Most patients are maintained in a disease-suppressed state on daily TKI therapy for several...

Descripción completa

Detalles Bibliográficos
Autores principales: Ross, Theodora S, Mgbemena, Victoria E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904890/
https://www.ncbi.nlm.nih.gov/pubmed/27308345
http://dx.doi.org/10.4161/23723548.2014.963450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904890/
https://www.ncbi.nlm.nih.gov/pubmed/27308345
http://dx.doi.org/10.4161/23723548.2014.963450

Ejemplares similares